Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85–90.

Article  CAS  PubMed  Google Scholar 

Hofman MS, Violet J, Hicks RJ, et al. [177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825–33.

Article  CAS  PubMed  Google Scholar 

Hofman MS, Emmett L, Sandhu S, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797–804.

Article  CAS  PubMed  Google Scholar 

Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091–103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herrmann K, Rahbar K, Eiber M, Sparks R, Baca N, Krause BJ, Lassmann M, Jentzen W, Tang J, Chicco D, Klein P, Blumenstein L, Basque JR, Kurth J. Renal and Multiorgan Safety of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate Cancer in the VISION Dosimetry Substudy. J Nucl Med. 2024;65(1):71–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Violet J, Jackson P, Ferdinandus J, et al. Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate Cancer: correlations between Pretherapeutic Imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60(4):517–23.

Article  CAS  PubMed  Google Scholar 

Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, et al. Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:42–51.

Article  CAS  PubMed  Google Scholar 

Scarpa L, Buxbaum S, Kendler D, Fink K, Bektic J, Gruber L, et al. The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates. Eur J Nucl Med Mol Imaging. 2017;44:788–800.

Article  CAS  PubMed  Google Scholar 

Nautiyal A, Jha AK, Mithun S, Rangarajan. Venkateshb,c. Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review. Nucl Med Commun. 2022;43(4):369–77.

Article  CAS  PubMed  Google Scholar 

Council Directive. 2013/59/Euratom of 5 December 2013 laying down basic safety standards for protection against the dangers arising from exposure to ionising radiation, and repealing Directives 89/618/Euratom, 90/641/Euratom, 96/29/Euratom, 97/43/Euratom and 2003/122/Euratom. OJ L 13, 17.1.2014, pp. 1–73.

Konijnenberg M, Herrmann K, Kobe C, et al. EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy. Eur J Nucl Med Mol Imaging. 2021;48:67–72.

Article  PubMed  Google Scholar 

Kratochwil C, Fendler WP, Eiber M, et al. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50:2830–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sjögreen-Gleisner K, Flux G, Bacher K, Chiesa C, de Nijs R, Kagadis GC, Lima T, Georgosopoulou ML, Gabiña PM, Nekolla S, Peters S, Santos J, Sattler B, Stokke C, Tran-Gia J, Gilligan P, Bardiès M. EFOMP policy statement 19: Dosimetry in nuclear medicine therapy - molecular radiotherapy. Phys Med. 2023;116:103166.

Article  PubMed  Google Scholar 

Barna S, Haug AR, Hartenbach M, Rasul S, Grubmüller B, Kramer G, Blaickner M. Dose calculations and dose-effect relationships in 177Lu-PSMA I&T Radionuclide Therapy for metastatic castration-resistant prostate Cancer. Clin Nucl Med. 2020;45(9):661–7.

Article  PubMed  Google Scholar 

Völter F, Mittlmeier L, Gosewisch A, Brosch-Lenz J, Gildehaus FJ, Zacherl MJ, Beyer L, Stief CG, Holzgreve A, Rübenthaler J, Cyran CC, Böning G, Bartenstein P, Todica A, Ilhan H. Correlation of an index-lesion-based SPECT Dosimetry Method with Mean Tumor dose and clinical outcome after 177Lu-PSMA-617 Radioligand Therapy. Diagnostics (Basel). 2021;11(3):428.

Article  PubMed  Google Scholar 

Peters SMB, Privé BM, de Bakker M, de Lange F, Jentzen W, Eek A, Muselaers CHJ, Mehra N, Witjes JA, Gotthardt M, Nagarajah J, Konijnenberg MW. Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome. Eur J Nucl Med Mol Imaging. 2022;49(2):460–9.

Article  CAS  PubMed  Google Scholar 

Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, Robertson JS, Howell RW, Wessels BW, Fisher DR, Weber DA, Brill AB. MIRD pamphlet 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40(2):S37–61.

Google Scholar 

Karimzadeh A, Soeiro P, Feuerecker B et al. Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of 177Lu-PSMA I&T [published online ahead of print, 2023 Sep 7]. J Nucl Med. 2023;jnumed.123.265878.

Kurth J, Heuschkel M, Tonn A, et al. Streamlined schemes for Dosimetry of 177Lu-Labeled PSMA Targeting Radioligands in therapy of prostate Cancer. Cancers (Basel). 2021;13(15):3884.

Article  CAS  PubMed  Google Scholar 

Mix M, Renaud T, Kind F, et al. Kidney doses in 177Lu-Based Radioligand Therapy in prostate Cancer: is dose estimation based on reduced dosimetry measurements feasible? J Nucl Med. 2022;63:253–8.

Article  CAS  PubMed  Google Scholar 

Jackson PA, Hofman MS, Hicks RJ, Scalzo M, Violet J. Radiation dosimetry in 177Lu-PSMA-617 therapy using a single posttreatment SPECT/CT scan: a novel methodology to generate time and tissue-specific dose factors. J Nucl Med. 2020;61(7):1030–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brosch-Lenz J, Delker A, Völter F, et al. Toward single-time-point image-based dosimetry of 177Lu-PSMA-617 therapy. J Nucl Med. 2023;64(5):767–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peters SMB, Mink MCT, Privé BM, et al. Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation. EJNMMI Res. 2023;13:6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heck MM, Tauber R, Schwaiger S, et al. Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177 Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur Urol. 2019;75:920–6.

Article  CAS  PubMed  Google Scholar 

Karimzadeh A, Heck M, Tauber R, et al. 177Lu-PSMA-I&T for treatment of metastatic castration-resistant prostate Cancer: Prognostic Value of Scintigraphic and clinical biomarkers. J Nucl Med. 2023;64(3):402–9.

Article  CAS  PubMed  Google Scholar 

Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57:1006–13.

Article  CAS  PubMed  Google Scholar 

Okamoto S, Thieme A, Allmann J, D’Alessandria C, Maurer T, Retz M, et al. Radiation Dosimetry for 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions. J Nucl Med. 2017;58:445–50.

Article  CAS  PubMed  Google Scholar 

Barna S, Haug AR, Hartenbach M, Rasul S, Grubmüller B, Kramer G, Blaickner M. Dose calculations and dose-effect relationships in 177Lu-PSMA I&T Radionuclide Therapy for metastatic castration-resistant prostate Cancer. Clin Nucl Med. 2020;45(9):661–7.

Article  PubMed  Google Scholar 

Schuchardt C, Zhang J, Kulkarni HR, Chen X, Müller D, Baum RP. Prostate-specific membrane Antigen Radioligand Therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate Cancer: comparison of Safety, Biodistribution, and Dosimetry. J Nucl Med. 2022;63(8):1199–207.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Uijen MJM, Privé BM, van Herpen CML, Westdorp H, van Gemert WA, de Bakker M, Gotthardt M, Konijnenberg MW, Peters SMB, Nagarajah J. Kidney absorbed radiation doses for [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry. Nucl Med Commun. 2023;44(4):270–5.

Article  CAS  PubMed